Humco merging with Fargon


Humco is merging with Fagron for a value of up to US $70 million.

Founded in 1872, Humco serves over 45,000 pharmacies and is anchored by its leading non-sterile, innovative patented delivery vehicles (including topical and transdermal creams, syrups and suspensions) and branded pharmaceutical products.

This mutually beneficial merger will allow Humco to strengthen and add value to customers through Fagron’s extensive line of Active Pharmaceutical Ingredients, product portfolio and strong research and development. While still working under the Humco brand, increased financial flexibility will facilitate continued investment into innovative pharmaceutical products for patients and pharmacies globally as well as into Humco’s state-of-the-art FDA registered, cGMP compliant production facility in Texarkana, Texas.

“I am pleased to welcome Humco to the Fagron Group. Their high-quality portfolio of branded pharmaceutical products and widely used patented delivery vehicles that are supplied to a broad customer base of pharmacy chains and wholesalers in the USA, is highly complementary to our extensive range of active pharmaceutical ingredients. Humco is an excellent strategic fit for Fagron. By combining the two companies we create a strong competitive company with significant scale, strengthening our market position in the USA. Our global footprint and leading market positions in Europe and South-America will enable us to successfully launch and grow the innovative branded pharmaceutical products and delivery vehicles of Humco outside the USA. We look forward to welcoming the Humco employees to the Fagron family,” said Rafael Padilla, Fagron’s Chief Executive Officer.

Gregory Pulido, Humco’s Chairman and Chief Executive Officer, will transition to the role of Executive Chairman while Andrew Pulido, Humco’s current President, Global Pharmaceuticals, will assume the sole role of President at Humco.

Andrew Pulido said, “I am honored to become Humco’s President at such an exciting time. The joint activities of Fagron and Humco are extremely well positioned to capitalize on growth opportunities in the USA and around the world. I am confident that our expertise, creativity and dedication will enable us to offer increased value to our customers, suppliers, and employees as well as to further extend Fagron’s leadership in the market for personalized medication.”

Copyright 2021 Nexstar Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Trending Stories

Loving Living Local 600x600

Don't Miss